Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is PFE's Net Revenue (Sales)?

  Pfizer Inc ( PFE ) |
1994 - 2021 (28 years)

Net Revenue (Sales) is 
$35.4B (1Y -24.9% )

PFE Stock Price & Net Revenue (Sales)

Net Revenue (Sales) for PFE competitors.
AMGN AZN GSK NVS ABT BMY JNJ LLY MRK MYL
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Net Revenue (Sales)

chevron_right 2021 $5.9B -0.4x
( -2.0% / year avg)
chevron_left 1994 $10.5B
vertical_align_top Peak $66.7B +10.2x
vertical_align_bottom Bottom $5.9B
arrow_drop_up # Up Years 14 14 of 28
years up.
arrow_drop_down # Down Years 14
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • PFE's stock price has rallied +6,168,233% from $0.0 in 1994 , or -154203.3x faster than it's net revenue (sales) over the same period.
  • If PFE shrinks it's stock at the same rate as it's net revenue (sales) (-2.0%/year) , it's stock price will shrink +81.7% and hit $30.24 over the next 10 years.
  • PFE's stock price has gone up 10 of the 14 years (+71%) it's net revenue (sales) were also up.
  • PFE Historical Net Revenue (Sales) Table
    in $ million
    Year Net Revenue (Sales) YoY % Change Stock Price YoY % Change (Stock Price)
    4/1/2021 $5,947 -87.8% $37.01 -2.1%
    4/1/2020 $48,648 -8.3% $37.82 -4.4%
    4/1/2019 $53,039 -0.6% $39.54 19.5%
    4/1/2018 $53,373 1.7% $33.09 14.3%
    4/1/2017 $52,471 -1.5% $28.95 -2.3%
    4/1/2016 $53,244 11.1% $29.62 3.4%
    4/1/2015 $47,922 -4.2% $28.65 21.4%
    4/1/2014 $50,045 -7.6% $23.61 12.5%
    4/1/2013 $54,184 -7.4% $20.99 29.0%
    4/1/2012 $58,535 -12.2% $16.28 6.3%
    4/1/2011 $66,679 0.7% $15.32 46.8%
    4/1/2010 $66,240 44.6% $10.43 4.3%
    4/1/2009 $45,818 -6.1% $10.0 -16.1%
    4/1/2008 $48,820 1.4% $11.93 -25.7%
    4/1/2007 $48,151 -2.5% $16.05 20.9%
    4/1/2006 $49,361 -0.8% $13.28 -12.2%
    4/1/2005 $49,781 -3.8% $15.12 -19.0%
    4/1/2004 $51,758 36.4% $18.67 15.9%
    4/1/2003 $37,950 13.4% $16.11 -8.8%
    4/1/2002 $33,477 44.9% $17.66 -18.4%
    4/1/2001 $23,104 -21.5% $21.63 -9.8%
    4/1/2000 $29,414 20.8% $23.98 27.0%
    4/1/1999 $24,349 0.7% $18.88 3.3%
    4/1/1998 $24,180 76.7% $18.29 126.1%
    4/1/1997 $13,682 -13.5% $8.09 59.4%
    4/1/1996 $15,818 7.2% $5.07 84.7%
    4/1/1995 $14,758 41.1% $2.75 93.8%
    4/1/1994 $10,460 - $1.42 -

  • About
    Industry: Drug Manufacturers General
    Sector: Healthcare
    Country: US
    IPO Date: 1/17/1944
    Stonk Exchange: NYSE
    • Pfizer Inc
    • engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare.
    • The company is headquartered in New York City, New York and currently employs 92,400 full-time employees.
    • The firm is engaged in the discovery, development and manufacture of healthcare products.
    • Its global portfolio includes medicines and vaccines.
    • The firm manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
    • IH focuses on developing and commercializing medicines and vaccines.
    • IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare.
    • EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems.
    • EH also includes a research and development (R&D) organization, as well as its contract manufacturing business.
    • Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

  • "The Top Line"

    The revenue (or sales) is the value of a company's sales of goods and services to its customers. Although a company's bottom line (its net income) gets most of the attention from investors, the top line is where the revenue or income process begins. Also, in the long run, profit margins on a company's existing products tend to eventually reach a maximum that is difficult to improve. Thus, companies typically can grow no faster than their revenues.

    For more detailed definitions, please see Investopedia.